Blay JY - Search Results

1

Management of pediatric non-Hodgkin's lymphoma.

Blay JY, Louis D, Bouffet E, Thiesse P, Biron P, Favrot MC, Brunat-Mentigny M, Philip T. Blay JY, et al. Blood Rev. 1991 Jun;5(2):90-7. doi: 10.1016/0268-960x(91)90040-j. Blood Rev. 1991. PMID: 1912759 Review.

2

Tumor necrosis factor as an autocrine growth factor for neuroblastoma.

Goillot E, Combaret V, Ladenstein R, Baubet D, Blay JY, Philip T, Favrot MC. Goillot E, et al. Among authors: blay jy. Cancer Res. 1992 Jun 1;52(11):3194-200. Cancer Res. 1992. PMID: 1317260

3

High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases.

Dumontet C, Biron P, Bouffet E, Blay JY, Meckenstock R, Chauvin F, Philip I, Clavel M, Brunat-Mentigny M, Philip T. Dumontet C, et al. Among authors: blay jy. Bone Marrow Transplant. 1992 Nov;10(5):405-8. Bone Marrow Transplant. 1992. PMID: 1464000

4

[Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment].

Blay JY, Négrier S, Combaret V, Merrouche Y, Mercatello A, Moskovtchenko JF, Philip T, Favrot M. Blay JY, et al. Bull Cancer. 1992;79(1):55-65. Bull Cancer. 1992. PMID: 1520953 French.

5

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.

Négrier S, Mercatello A, Bret M, Thiesse P, Blay JY, Coronel B, Merrouche Y, Oskam R, Franks CR, Clavel M, et al. Négrier S, et al. Among authors: blay jy. Br J Cancer. 1992 May;65(5):723-6. doi: 10.1038/bjc.1992.152. Br J Cancer. 1992. PMID: 1586600 Free PMC article. Clinical Trial.

6

TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.

Favrot M, Combaret V, Blay JY, Capdeville R, Zhou DC, Clapisson G, Chouaib S, Franks CR, Philip T. Favrot M, et al. Among authors: blay jy. Eur Cytokine Netw. 1990 Oct-Nov;1(4):221-7. Eur Cytokine Netw. 1990. PMID: 2104243

7

Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.

Favrot M, Capdeville R, Combaret V, Zhou DC, Clapisson G, Banchereau J, Franks CR, Chouaib S, Blay JY, Philip T. Favrot M, et al. Among authors: blay jy. Eur Cytokine Netw. 1990 Aug-Sep;1(3):141-7. Eur Cytokine Netw. 1990. PMID: 2129798

8

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.

Blay JY, Favrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaemmerlen P, Franks CR, Philip T. Blay JY, et al. Cancer Res. 1990 Apr 15;50(8):2371-4. Cancer Res. 1990. PMID: 2317822

9

Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients.

Chambrier C, Mercatello A, Tognet E, Cottet-Emard JM, Cohen R, Blay JY, Favrot M, Philip T, Beylot M. Chambrier C, et al. Among authors: blay jy. J Biol Response Mod. 1990 Apr;9(2):251-5. J Biol Response Mod. 1990. PMID: 2341864

10

The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression.

Blay JY, Bouhour D, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, Biron P. Blay JY, et al. Blood. 1995 Oct 15;86(8):2922-9. Blood. 1995. PMID: 7579384 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,030 results

Search Page

Filters